Cargando…

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

BACKGROUND: Dolutegravir (DTG) and boosted darunavir (bDRV) are potent antiretrovirals with a high resistance barrier and might be valuable switch options for people with HIV (PWH). METHODS: DUALIS, a randomized, open-label, phase 3b, noninferiority clinical trial, compared the switch to DTG + bDRV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinner, Christoph D, Kümmerle, Tim, Schneider, Jochen, Cordes, Christiane, Heiken, Hans, Stellbrink, Hans-Jürgen, Krznaric, Ivanka, Scholten, Stephan, Jensen, Björn, Wyen, Christoph, Viehweger, Marin, Lehmann, Clara, Sprinzl, Martin, Stoehr, Albrecht, Bickel, Markus, Jessen, Heiko, Obst, Wilfried, Spornraft-Ragaller, Petra, Khaykin, Pavel, Wolf, Eva, Boesecke, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491710/ https://www.ncbi.nlm.nih.gov/pubmed/32965277 http://dx.doi.org/10.1093/ofid/ofaa356

Ejemplares similares

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

Reply: Beyond Viral Suppression
por: Spinner, Christoph D, et al.
Publicado: (2021)

Prevalence and antibiotic resistance of rectal Mollicutes in HIV-infected men who have sex with men at the University Hospital of Dresden, Germany
por: Spornraft-Ragaller, Petra, et al.
Publicado: (2020)

Antibiotic Resistance and Genotypes of Mycoplasma genitalium during a Resistance-Guided Treatment Regime in a German University Hospital
por: Dumke, Roger, et al.
Publicado: (2021)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient
por: Lee, Marcel, et al.
Publicado: (2015)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Third generation Dual Mobility Cups: could be the future in total hip arthroplasty? A five-year experience with dualis
por: Paderni, Stefania, et al.
Publicado: (2021)

Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone
por: Spornraft-Ragaller, P, et al.
Publicado: (2011)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )
por: Osiyemi, Olayemi, et al.
Publicado: (2022)

Is there any evidence for milder courses of monkeypox virus infections with childhood smallpox vaccination?
por: Hoffmann, Christian, et al.
Publicado: (2022)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir
por: Chen, Ying, et al.
Publicado: (2022)

Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort
por: Crowell, Trevor A., et al.
Publicado: (2021)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2020)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Defining the noninferiority margin and analysing noninferiority: An overview
por: Althunian, Turki A., et al.
Publicado: (2017)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4(+) Count, and WHO Clinical Staging
por: Spinner, Christoph D, et al.
Publicado: (2018)

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2013)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Noninferiority trials
por: Snapinn, Steven M
Publicado: (2000)

What an emergency physician needs to know about acute care of cardiac arrhythmias
por: Stellbrink, Christoph
Publicado: (2010)

Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma
por: Linge, Annett, et al.
Publicado: (2018)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
por: Donga, Prina, et al.
Publicado: (2023)

Understanding noninferiority trials
por: Hahn, Seokyung
Publicado: (2012)

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
por: Härter, Georg, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_05k5kelt06o2vgep8s0iq3vjub